Kestra Medical CBO granted 22,704 shares

Moran Timothy P. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Moran Timothy P. reported acquisition or exercise transactions in this Form 4 filing.

Kestra Medical Technologies reported that Chief Business Officer Timothy P. Moran received a grant of 22,704 restricted stock units (RSUs), each representing one common share at settlement. These RSUs vest over three years, with one-third vesting on each anniversary of June 3, 2026, subject to his continued service. Following this award, Moran holds 42,261 common shares directly. This is a compensation-related equity grant rather than an open-market stock purchase or sale.

Insights

Equity Compensation Analyst

Routine three-year RSU grant to Kestra executive, no open-market trading.

Chief Business Officer Timothy P. Moran received 22,704 RSUs, a common form of long-term equity compensation. Each RSU can settle into one common share, aligning part of his pay with future company performance.

The RSUs vest in three equal installments on each anniversary of June 3, 2026, contingent on continued service. This creates a retention incentive, as unvested units are typically forfeited if employment ends before vesting dates.

No shares were bought or sold in the market and no options were exercised, so there is no immediate trading signal. Future filings around each vesting date may show actual share delivery or any related tax-withholding transactions.

Insider Trade Summary

Grant/Award: 22,704 shares

Grant/Award 1 txn

Insider Moran Timothy P.

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	22,704	$0.00	$0.00

Holdings After Transaction: Common Shares — 42,261 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

Key Figures

RSU grant size: 22,704 units Post-grant holdings: 42,261 shares Transaction price: $0.0000 per share +2 more

5 metrics

RSU grant size 22,704 units Restricted stock units awarded to Chief Business Officer

Post-grant holdings 42,261 shares Common shares held directly after transaction

Transaction price $0.0000 per share RSU grant price, indicates compensation award

Vesting start anniversary June 3, 2026 First of three annual vesting anniversaries

Vesting schedule 1/3 per year over 3 years Service-based vesting of RSU grant

Key Terms

restricted stock units ("RSU"), vest, continued service, common share

4 terms

restricted stock units ("RSU") financial

"Represents restricted stock units ("RSU") that entitle the Reporting Person to receive"

vest financial

"Subject to the Reporting Person's continued service, the RSUs will vest over three years"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continued service financial

"Subject to the Reporting Person's continued service, the RSUs will vest"

common share financial

"to receive, at settlement, one common share of Kestra Medical Technologies, Ltd."

A common share is a type of ownership in a company that gives the holder a claim to a portion of the company’s profits and assets. It often comes with voting rights, allowing shareholders to participate in decisions about the company’s direction. For investors, owning common shares can mean potential for growth and income, but also involves a higher level of risk compared to other types of investments.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Timothy P. Moran report in the Kestra Medical Technologies (KMTS) Form 4?

Timothy P. Moran reported receiving a grant of 22,704 restricted stock units. Each RSU entitles him to one Kestra Medical common share at settlement, making this a compensation award rather than an open-market stock purchase or sale.

How do the 22,704 RSUs granted to KMTS executive Timothy P. Moran vest?

The 22,704 RSUs vest over three years, with one-third vesting on each anniversary of June 3, 2026. Vesting is subject to Moran’s continued service, so he must remain with Kestra Medical to receive each installment.

Did the KMTS Form 4 show any open-market stock purchases or sales by Timothy P. Moran?

No, the filing only shows a grant of restricted stock units with a zero transaction price. This indicates an equity compensation award, not an open-market buy or sell transaction involving Kestra Medical Technologies common shares.

How many Kestra Medical Technologies (KMTS) shares does Timothy P. Moran hold after this RSU grant?

After the RSU award, Timothy P. Moran is reported as directly holding 42,261 common shares. This figure reflects his position following the grant of 22,704 restricted stock units disclosed in the Form 4 filing.

What type of security was granted to Timothy P. Moran in the KMTS Form 4 filing?

The filing shows a grant of restricted stock units, or RSUs, tied to Kestra Medical common shares. Each RSU represents a right to receive one share at settlement, subject to the three-year service-based vesting schedule described in the footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 06:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moran Timothy P.

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE

SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/03/2026		A		22,704(1)	A	$0	42,261	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

	/s/ Traci S. Umberger as attorney-in-fact for Timothy P. Moran	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)